Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Active not recruiting 2Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 413Carcinoma, Non-Small-Cell Lung 286Prostatic Neoplasms 208Neoplasms 204Neoplasm Metastasis 180Melanoma 164Multiple Myeloma 158Colorectal Neoplasms 158Leukemia, Myeloid, Acute 143Lung Neoplasms 132Leukemia 126Lymphoma 118Pancreatic Neoplasms 117Recurrence 111Ovarian Neoplasms 111Leukemia, Lymphocytic, Chronic, B-Cell 110Lymphoma, Non-Hodgkin 105Carcinoma, Renal Cell 104Brain Neoplasms 90Myelodysplastic Syndromes 88Precursor Cell Lymphoblastic Leukemia-Lymphoma 86Glioblastoma 85Lymphoma, Large B-Cell, Diffuse 80Lymphoma, Follicular 79Carcinoma, Hepatocellular 79Head and Neck Neoplasms 77Squamous Cell Carcinoma of Head and Neck 76Urinary Bladder Neoplasms 66Stomach Neoplasms 61Hodgkin Disease 60

Interventions

Surgical Procedures, Operative 1Immunohistochemistry 1Erlotinib Hydrochloride 1Congresses as Topic 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Terminated × Pancreatic Intraductal Neoplasms × Clear all
NCT00482625 2014-10-16

Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Terminated
6 enrolled 8 charts
Gastrointestinal

Pancreatic Intraductal Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡